Baseline demographics and clinical characteristics of the pre– and post–CAR-Tx cohorts (N = 45)
| Baseline characteristics . | Cohort . | |
|---|---|---|
| Pre–CAR-Tx (n = 21) . | Post–CAR-Tx (n = 24) . | |
| Age, y (range) | 67 (41-84) | 59 (39-81) |
| Sex, n (%) | ||
| Male | 14 (66.7) | 15 (62.5) |
| Race, n (%) | ||
| White | 19 (90.5) | 24 (100) |
| Disease, n (%) | ||
| Lymphoma | 16 (76.2) | 15 (62.5) |
| ALL | 0 | 1 (4.2) |
| CLL | 0 | 2 (8.3) |
| MM | 3 (14.3) | 6 (25.0) |
| WM | 2 (9.5) | 0 |
| Target, n (%) | ||
| CD19 | 15 (71.4) | 16 (66.7) |
| CD20 | 3 (14.3) | 2 (8.3) |
| BCMA | 3 (14.3) | 6 (25.0) |
| CAR-Tx type, n (%) | ||
| Commercial | 16 (76.2) | 6 (25.0) |
| Investigational | 5 (23.8) | 18 (75.0) |
| Vaccine type, n (%) | ||
| mRNA-1273 | 6 (28.6) | 12 (50.0) |
| BNT162b2 | 15 (71.4) | 12 (50.0) |
| IgG level, median (IQR), mg/dL∗ | — | 458 (363-552) |
| CD-19+ B cells, median (IQR), cells/mL∗ | — | 17 (0-160) |
| CD-4+ T cells, median (IQR), cells/mL∗ | — | 345 (219-559) |
| Time from second vaccine to sample collection, mo, median (IQR) | 4.1 (1.9-5.4) | 2.0 (0.7-2.4) |
| Time from CAR-Tx to second vaccination, mo, median (IQR) | −4.3 (−5.9 to −2.4) | 19.0 (10.5-29.2) |
| Time interval between first and second vaccination, d, median (IQR) | 21 (21-28) | 28 (21-29) |
| Time interval between second and third vaccination, d, median (IQR) | — | 142 (117-206)† |
| Baseline characteristics . | Cohort . | |
|---|---|---|
| Pre–CAR-Tx (n = 21) . | Post–CAR-Tx (n = 24) . | |
| Age, y (range) | 67 (41-84) | 59 (39-81) |
| Sex, n (%) | ||
| Male | 14 (66.7) | 15 (62.5) |
| Race, n (%) | ||
| White | 19 (90.5) | 24 (100) |
| Disease, n (%) | ||
| Lymphoma | 16 (76.2) | 15 (62.5) |
| ALL | 0 | 1 (4.2) |
| CLL | 0 | 2 (8.3) |
| MM | 3 (14.3) | 6 (25.0) |
| WM | 2 (9.5) | 0 |
| Target, n (%) | ||
| CD19 | 15 (71.4) | 16 (66.7) |
| CD20 | 3 (14.3) | 2 (8.3) |
| BCMA | 3 (14.3) | 6 (25.0) |
| CAR-Tx type, n (%) | ||
| Commercial | 16 (76.2) | 6 (25.0) |
| Investigational | 5 (23.8) | 18 (75.0) |
| Vaccine type, n (%) | ||
| mRNA-1273 | 6 (28.6) | 12 (50.0) |
| BNT162b2 | 15 (71.4) | 12 (50.0) |
| IgG level, median (IQR), mg/dL∗ | — | 458 (363-552) |
| CD-19+ B cells, median (IQR), cells/mL∗ | — | 17 (0-160) |
| CD-4+ T cells, median (IQR), cells/mL∗ | — | 345 (219-559) |
| Time from second vaccine to sample collection, mo, median (IQR) | 4.1 (1.9-5.4) | 2.0 (0.7-2.4) |
| Time from CAR-Tx to second vaccination, mo, median (IQR) | −4.3 (−5.9 to −2.4) | 19.0 (10.5-29.2) |
| Time interval between first and second vaccination, d, median (IQR) | 21 (21-28) | 28 (21-29) |
| Time interval between second and third vaccination, d, median (IQR) | — | 142 (117-206)† |